Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial.

Name: Kaimen Rigor review — Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial.
Item: Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial.
Rating: 59
Author: Alpha1

Oehrn CR, Cernera S, Hammer LH, Shcherbakova M, Yao J, Hahn A, Wang S, Ostrem JL, Little S, Starr PA

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 1.5★ (Critical), 0 critical, 5 high issues for “Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial.

Oehrn CR, Cernera S, Hammer LH, Shcherbakova M, Yao J, Hahn A, Wang S, Ostrem JL, Little S, Starr PA

Read full text (PMC)

DOI

10.1038/s41591-024-03196-z

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/38be91f8-27a5-41f4-8f36-6132b178958f" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/38be91f8-27a5-41f4-8f36-6132b178958f/badge" alt="Kaimen Rigor review — 1.5★ (Critical), 0 critical, 5 high issues for “Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson&#39;s disease: a blinded randomized feasibility trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

9ac44f64437db4ac80aea63be7f6dd63ea58aff1feb454270263b1f78f919299

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial.

Oehrn CR, Cernera S, Hammer LH, Shcherbakova M, Yao J, Hahn A, Wang S, Ostrem JL, Little S, Starr PA

Paper source

Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

1.5 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
CitationsUnresolved reference ×2−0.5★
ReportingStudy design partially met−0.25★
ReportingBiological variables partially met−0.25★
ReportingStatistical analysis partially met−0.25★
LinksDead data/code link−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on patient-reported symptom duration (percentage of awake time with most bothersome symptom) and quality of life (EQ-5D), which are clinical outcomes, not surrogate biomarkers. However, the neural signal (stimulation-entrained gamma oscillations) used to drive adaptive DBS is a surrogate biomarker, and the paper does not provide validated evidence linking this surrogate to the clinical outcome, nor does it demonstrate target engagement at the tested dose beyond showing that the signal tracks medication states. The efficacy claim itself is based on clinical outcomes, so the surrogate verdict is not applicable to the primary claim.
“We identified stimulation-entrained gamma oscillations in the subthalamic nucleus or motor cortex as optimal markers of high and low dopaminergic states and their associated residual motor signs in all four patients. We then demonstrate improved motor…”
Find in source
02Declared data/code link does not resolve
mediumAvailabilityrecomputedFull detail
Dead link — nothing to verify.
“https://openmind-consortium.github.io”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 103AuthenticityData authenticity concerns 304DisclosureReporting gaps 205AvailabilityBroken references and links 06Copyedit3 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted feasibility trial with strong ethical approvals, clear resource identification, and transparent data/code sharing. The main weaknesses are incomplete reporting of randomization/blinding methods, limited demographic detail, and imprecise p-value reporting.

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence required reconciliation. The statistics verification component checked 0 tests due to threshold-only p-values, so no statistical results were machine-verified; the citation component flagged 2 references as not found in registry (the data and code DOIs, which are not true citations but data/code identifiers).

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions

1 finding · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

3 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Data look implausibly cleanAssessed

3 integrity concerns flagged (0 high).

Reporting gaps

3 findings · worst high

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
Biological variables underreported (sex, age, strain)Assessed
Study-design details incomplete (controls, blinding, power)Assessed

Eight Dimensions5 pass · 3 warn

The introduction thoroughly reviews prior research on DBS, adaptive DBS, and neural biomarkers, acknowledging limitations of previous studies (e.g., in-laboratory settings, lack of individualized approaches). The rationale linking the premise to the study objectives is strong, and the study directly addresses prior limitations by using a data-driven, home-based approach.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale for the study.

Evidence

“However, these results were derived from in-laboratory studies and group-level analyses, lacking individualized, data-driven approaches.”

Introduction ¶1Find in source

“Here, we conducted a blinded, randomized, cross-over feasibility trial with four PD patients (across six independently optimized hemispheres) to identify neural biomarkers of motor signs during active stimulation and compare the effects of aDBS to optimized cDBS during normal, unrestricted, daily life.”

Introduction ¶4Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior work on DBS and adaptive stimulation, identifying gaps, and providing a logical rationale for the study.

Evidence

“However, these results were derived from in-laboratory studies and group-level analyses, lacking individualized, data-driven approaches.”

Introduction ¶2Find in source

Introduction ¶3Find in source

The trial is described as blinded and randomized, but the randomization method (e.g., sequence generation, allocation concealment) is not specified. Blinding is mentioned but not detailed (e.g., who was blinded, how blinding was maintained). A power analysis is provided using binomial distribution analysis, which is adequate for an N-of-1 design. Inclusion/exclusion criteria are clearly pre-specified. Outlier handling is not explicitly described, though some outliers are mentioned in figure legends. Controls are inherent in the crossover design (cDBS as control). Independent replication is not applicable for a single feasibility trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsINADEQUATE

outlier handlingINADEQUATE

randomization unitINADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The study design is appropriate for a feasibility trial but lacks detailed reporting of randomization and blinding methods.

Evidence

“This workflow culminated in a blinded, randomized, cross-over comparison between aDBS and cDBS”

Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial.

Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial.

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting

Numerical inconsistencies

Overstated conclusions

Data authenticity concerns

Reporting gaps

Broken references and links

Copyediting